Japan Approves First RSV Vaccine Aimed at Adults 60 Years or Older
![](https://japannews.yomiuri.co.jp/wp-content/uploads/2023/02/health-ministry-1.jpg)
The Health, Labor and Welfare Ministry
15:35 JST, September 26, 2023
The Health, Labor and Welfare Ministry on Monday formally approved the respiratory syncytial virus vaccine developed by British pharmaceutical company GSK PLC. It is the first time Japan has approved an RSV vaccine for use in adults aged 60 or older.
The RS virus causes symptoms like those of the common cold but can lead to severe pneumonia for those with weakened immune systems, including infants and elderly people.
According to GSK, the vaccine lowered the risk of pneumonia and bronchitis by about 80% in adults aged 60 or older in its vaccine efficacy trials.
U.S. pharmaceutical company Pfizer Inc. has also applied for approval of its RSV vaccine.
"Science & Nature" POPULAR ARTICLE
-
Cubans Put Asian Silkworms to Work for Artisans in Experimental Project
-
Fault Near Fukui Pref. Nuclear Power Plant May Be Active; Survey To Determine Whether It Extends Directly Under Reactor
-
Startup to Apply For Approval to Produce Heart Cell Sheets from iPS Cells for Heart Disease Treatment
-
Japanese Telecommunications Giants Unveil Plans to Expand Space Businesses; KDDI Hopes to Create Environment for 5G Use on Moon
-
Chinese Fossil Reveals Evolution of Skin in Feathered Dinosaurs
JN ACCESS RANKING